Âne anti-Chévre IgG (Heavy & Light Chain) Anticorps (IRDye680LT)

Détails pour le produit réf. ABIN2169649, Fournisseur: Connectez-vous pour afficher
Antigène
Épitope
Heavy & Light Chain
5027
2578
1931
1069
1007
857
330
299
35
34
31
8
7
7
3
3
2
2
1
1
1
1
1
1
Reactivité
Chévre
2912
2859
2405
1752
1484
796
623
442
381
380
355
340
307
293
208
148
139
114
41
29
27
25
12
11
9
8
6
5
5
5
4
4
4
4
4
4
4
4
3
3
3
2
2
1
1
1
1
1
Hôte
Âne
6893
4912
1877
895
703
401
92
54
52
21
9
8
5
5
2
1
1
Clonalité
Polyclonal
Conjugué
IRDye680LT
2235
1889
1740
1374
765
679
519
300
299
288
274
268
217
188
178
124
103
79
69
60
54
46
43
40
40
36
34
32
29
29
27
27
27
27
27
27
27
27
22
22
19
19
19
19
16
15
15
15
15
15
14
12
12
11
10
10
9
9
9
9
9
9
8
8
8
8
8
7
7
6
6
6
6
6
6
5
5
5
5
5
4
4
4
4
4
4
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
Application
Immunofluorescence (IF), Immunohistochemistry (IHC), Western Blotting (WB)
Options
Fournisseur
Connectez-vous pour afficher
Supplier Product No.
Connectez-vous pour afficher
Immunogène Goat IgG
Isotype IgG
Fragment Whole molecule
Specificité Goat IgG
Based on ELISA, this antibody reacts with the heavy and light chains of goat IgG and sheep IgG.
 Réactivité croisée Mouton
Réactivité croisée (Details) This antibody was tested by Dot Blot and/or solid-phase adsorbed for minimal cross-reactivity with human, mouse, rabbit, rat, chicken, guinea pig, hamster, swine, and horse serum proteins, but may cross-react with immunoglobulins from other species.
Attributs du produit Blocking buffers and antibody diluents made with bovine serum albumin (BSA) and dry milk may contain IgG that reacts with anti-bovine IgG, anti-goat IgG, anti-horse IgG, and anti-sheep IgG antibodies. This can lead to a significant increase in background and/or reduction of secondary antibody titer for protein detection applications.
Purification Immunoaffinity chromatography
Domaine de recherche Immunology, Secondary Antibodies
Indications d'application Western blot: 1:20,000 Recommended
Optimum dilutions will vary and should be determined empirically.

NOTE: When using PVDF membranes for Western blotting, SDS (final concentration of 0.1 – 0.2%) and Tween® 20 (final concentration of 0.1 – 0.2%) must be added during the detection incubation step to avoid non-specific background staining.

  • IRDye 680LT secondary antibodies are suitable for immunofluorescent microscopy and other fluorescent imaging applications when using instrumentation with appropriate excitation and detection capabilities.
  • IRDye 680LT is not intended for In-Cell WesternTM assays or in vivo applications.
  • These antibodies are not recommended when getting up and running on system. Once established near-infrared protocols are optimized with IRDye 680RD, IRDye 680LT can be used to optimize signals in the 700 channel. Dilution range 1:20,000 – 1:40,000.
    Note: optimization may be required with IRDye 680LT. Please see pack insert for specific detergents/protocol modifications needed.
  • Commentaires

    • IRDye 680LT secondary antibodies have been proven to provide the brightest signal for Western blot detection in the 700 nm channel and are comparable to Alexa Fluor® 680 secondary antibodies.
    • Choose IRDye 680LT secondary antibodies to get high signal and for specific uses of detection in the 700nm channel.
    • We do not recommend to start with IRDye 680LT secondaries but rather to start with one of the IRDye 680RD secondaries.

    Restrictions For Research Use only
    Format Lyophilized
    Reconstitution Reconstitute with sterile, distilled water
    Concentration 1.0 mg/mL
    Buffer PBS, pH 7.4
    Agent conservateur Sodium azide
    Précaution d'utilisation This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Conseil sur la manipulation Protect from light.
    Stock 4 °C
    Produit citée dans: Mans, Banz, Mueller, Pabst: "The angiogenesis inhibitor vasostatin is regulated by neutrophil elastase-dependent cleavage of calreticulin in AML patients." dans: Blood, Vol. 120, Issue 13, pp. 2690-9, 2012 (PubMed).